Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis

Inclusion Criteria: * Sign Informed Consent * Use of condom by sexually active males for the entire duration of the study. * Best corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method). * Able and willing to comply with study protocol and follow protocol instructions. * Able to avoid any of the topical ocular or systemic excluded medications during the entire study period. * At least 1 year subject-reported or physician-diagnosed history (prior to Screen Visit) of allergic conjunctivitis during the ragweed season. * Positive skin prick test for short ragweed allergen within 12 months prior to Screen Visit. * Significant staff-assessed ocular redness in at least one region in each eye within the 3 hour period of allergen exposure in the EEC (Screen Visits). * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 1 week following the last dose of investigational product. * Presence of any ocular infection, history of ocular Herpes (simplex or zoster) or adenoviral infection in either eye. * History of any ocular infection, physician or subject diagnosed, within 30 days prior to Screen Visit. * Presence of glaucoma, past history of, or diagnosis of glaucoma or ocular hypertension. * Presence of blepharitis, active rosacea a…